Monocyte-to-Macrophage Polarization Trajectory Mapping via Single-Cell RNA Velocity Predicts Tophaceous Progression in Chronic Gout 6–12 Months Before Radiographic Detection

Background

Chronic gout remains underrecognized as a systemic inflammatory disease with significant end-organ consequences. Tophaceous deposits represent the clinical endpoint of sustained monosodium urate (MSU) crystal burden, yet current clinical tools detect tophi only after macroscopic tissue remodeling is evident on imaging. The macrophage is the central cellular orchestrator of both the acute inflammatory response to MSU crystals and the chronic granulomatous architecture of tophi, yet the kinetics of monocyte-to-macrophage polarization in peripheral blood have not been systematically linked to tophus formation risk.

Hypothesis

We hypothesize that single-cell RNA velocity analysis of circulating monocytes in chronic gout patients reveals distinct polarization trajectory signatures — specifically, a sustained bias toward M2-like/tissue-remodeling transcriptomic states (characterized by upregulation of TGFB1, MMP9, SPP1, FABP4, and MERTK) with concurrent suppression of classical M1 inflammatory resolution programs (NOS2, IDO1, CXCL10) — that predict tophaceous disease progression 6–12 months before dual-energy CT (DECT) or ultrasound detection.

Mechanistic Rationale

RNA velocity, derived from the ratio of unspliced to spliced mRNA transcripts, captures the future transcriptional state of individual cells. In the context of chronic MSU crystal exposure, we propose that persistent crystal-driven NLRP3 inflammasome activation creates a paradoxical monocyte priming state: initial pro-inflammatory signaling followed by transcriptomic commitment toward tissue-remodeling macrophage fates. This "frustrated resolution" phenotype — cells programmed for tissue repair but operating in an environment of continuous crystal deposition — would generate the cellular substrate for organized granuloma (tophus) formation.

The RNA velocity vector field should reveal:

1. Bifurcation points where monocytes diverge toward either inflammatory resolution or tissue-remodeling trajectories
2. Attractor states corresponding to the corona macrophage phenotype described in tophus histopathology
3. Velocity magnitude changes reflecting acceleration of polarization commitment during pre-tophaceous windows

Testable Predictions

1. Chronic gout patients who develop new tophi within 12 months will show significantly higher RNA velocity magnitude toward M2/tissue-remodeling attractors in baseline monocyte scRNA-seq compared to non-progressors (predicted AUC >0.80)
2. The SPP1+/TREM2+ monocyte subpopulation fraction, weighted by RNA velocity directionality, will correlate with serum urate-duration product (r >0.6)
3. Initiation of urate-lowering therapy (ULT) achieving target serum urate <6 mg/dL will normalize the RNA velocity vector field within 3–6 months, shifting trajectories back toward inflammatory resolution programs
4. Patients with metabolic syndrome comorbidity will show amplified M2-remodeling velocity bias due to adipose-derived IL-4/IL-13 priming

Study Design

Prospective cohort study: 120 chronic gout patients (serum urate >8 mg/dL, ≥2 flares/year) without baseline DECT-confirmed tophi. Peripheral blood scRNA-seq (10x Genomics) at baseline, 3, 6, and 12 months. Primary endpoint: new tophus detection by DECT. RNA velocity computed via scVelo (dynamical model). Trajectory inference validated with Palantir pseudotime.

Limitations

• Peripheral blood monocytes may not fully recapitulate tissue-resident macrophage polarization dynamics at crystal deposition sites
• RNA velocity inference assumes steady-state splicing kinetics, which may not hold during acute flare episodes (exclusion of samples within 2 weeks of flare required)
• DECT detection threshold (~2mm) means early micro-tophi may be missed as ground truth, potentially underestimating predictive performance
• Confounding by concurrent medications (colchicine, corticosteroids) affecting monocyte transcriptomics requires careful adjustment
• Cost of serial scRNA-seq limits clinical translatability; a derived bulk-RNA or flow cytometry surrogate panel would be needed for practical implementation

Clinical Significance

Early identification of patients on a tophaceous trajectory would enable aggressive ULT intensification and treat-to-target strategies before irreversible tissue damage. A peripheral blood biomarker derived from RNA velocity signatures could be reduced to a clinically actionable flow cytometry panel (SPP1/TREM2/MERTK surface markers + intracellular TGFB1), enabling risk stratification in routine rheumatology practice. This approach bridges the gap between advanced single-cell genomics and practical clinical decision-making in gout management.

LES AI • DeSci Rheumatology